Fluidigm is the leader in mass cytometry and microfluidics


Fundamental Analysis:
  • Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative. Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies
  • Fluidigm is a leader in mass cytometry. According to market research and Fluidigm , the mass cytometry market reached 2.7 billion with CAGR at 26% by 2025.
  • The Biden administration plans to spend about $ 1.6 billion on expanding Covid-19 testing programs.
  • Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China.According to company and third-party estimates, the addressable market for flow cytometry analysis in blood cancer in China is approximately $100 million for 2021–2023, and is growing at a double-digit rate.
  • The company shows stable revenue growth from year to year.

    Technical analysis:
  • From March 2020 to the end of September 2020, the 5th wave movement was completed.After that, a correction began, namely a double three, consisting of 2 zigzags.
  • At the moment, the company's shares are in the oversold zone according to the RSI indicator.
  • The company has several open gaps, namely in the following areas: $ 10-11, $ 15-19, $ 30-36 per share.
  • At the moment, the company's shares are at a strong support level .

    Disclosure: I am/we are long FLDM .

    I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.